NYSE:GKOS
Glaukos Corporation Stock News
$109.79
-0.620 (-0.562%)
At Close: May 17, 2024
Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock?
01:21pm, Tuesday, 14'th May 2024
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y
10:16am, Thursday, 02'nd May 2024
Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.
Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript
08:42pm, Wednesday, 01'st May 2024
Glaukos Corporation (NYSE:GKOS ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Chris Lewis - Vice President of IR & Corporate Affairs Tom Burns - Chairman and CEO Joe Gi
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
06:51pm, Wednesday, 01'st May 2024
Glaukos (GKOS) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.59 per share a year ago.
Glaukos Announces First Quarter 2024 Financial Results
04:05pm, Wednesday, 01'st May 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Announces the Release of its 2023 Sustainability Report
04:05pm, Tuesday, 16'th Apr 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
09:21am, Monday, 15'th Apr 2024
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?
10:26am, Friday, 12'th Apr 2024
Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
07:00am, Wednesday, 10'th Apr 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
11:46am, Monday, 08'th Apr 2024
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
01:05pm, Thursday, 04'th Apr 2024
Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
07:00am, Wednesday, 03'rd Apr 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
09:01am, Wednesday, 13'th Mar 2024
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y
10:00am, Thursday, 22'nd Feb 2024
Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.
Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript
11:13pm, Wednesday, 21'st Feb 2024
Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript
